Chronic lung diseases: prospects for regeneration and repair

COPD and idiopathic pulmonary fibrosis (IPF) together represent a considerable unmet medical need, and advances in their treatment lag well behind those of other chronic conditions. Both diseases involve maladaptive repair mechanisms leading to progressive and irreversible damage. However, our under...

Full description

Saved in:
Bibliographic Details
Published inEuropean respiratory review Vol. 30; no. 159; p. 200213
Main Authors Barnes, Peter J., Anderson, Gary P., Fagerås, Malin, Belvisi, Maria G.
Format Journal Article
LanguageEnglish
Published England European Respiratory Society 31.03.2021
Subjects
Online AccessGet full text
ISSN0905-9180
1600-0617
1600-0617
DOI10.1183/16000617.0213-2020

Cover

Abstract COPD and idiopathic pulmonary fibrosis (IPF) together represent a considerable unmet medical need, and advances in their treatment lag well behind those of other chronic conditions. Both diseases involve maladaptive repair mechanisms leading to progressive and irreversible damage. However, our understanding of the complex underlying disease mechanisms is incomplete; with current diagnostic approaches, COPD and IPF are often discovered at an advanced stage and existing definitions of COPD and IPF can be misleading. To halt or reverse disease progression and achieve lung regeneration, there is a need for earlier identification and treatment of these diseases. A precision medicine approach to treatment is also important, involving the recognition of disease subtypes, or endotypes, according to underlying disease mechanisms, rather than the current “one-size-fits-all” approach. This review is based on discussions at a meeting involving 38 leading global experts in chronic lung disease mechanisms, and describes advances in the understanding of the pathology and molecular mechanisms of COPD and IPF to identify potential targets for reversing disease degeneration and promoting tissue repair and lung regeneration. We also discuss limitations of existing disease measures, technical advances in understanding disease pathology, and novel methods for targeted drug delivery.
AbstractList COPD and idiopathic pulmonary fibrosis (IPF) together represent a considerable unmet medical need, and advances in their treatment lag well behind those of other chronic conditions. Both diseases involve maladaptive repair mechanisms leading to progressive and irreversible damage. However, our understanding of the complex underlying disease mechanisms is incomplete; with current diagnostic approaches, COPD and IPF are often discovered at an advanced stage and existing definitions of COPD and IPF can be misleading. To halt or reverse disease progression and achieve lung regeneration, there is a need for earlier identification and treatment of these diseases. A precision medicine approach to treatment is also important, involving the recognition of disease subtypes, or endotypes, according to underlying disease mechanisms, rather than the current “one-size-fits-all” approach. This review is based on discussions at a meeting involving 38 leading global experts in chronic lung disease mechanisms, and describes advances in the understanding of the pathology and molecular mechanisms of COPD and IPF to identify potential targets for reversing disease degeneration and promoting tissue repair and lung regeneration. We also discuss limitations of existing disease measures, technical advances in understanding disease pathology, and novel methods for targeted drug delivery.
COPD and idiopathic pulmonary fibrosis (IPF) together represent a considerable unmet medical need, and advances in their treatment lag well behind those of other chronic conditions. Both diseases involve maladaptive repair mechanisms leading to progressive and irreversible damage. However, our understanding of the complex underlying disease mechanisms is incomplete; with current diagnostic approaches, COPD and IPF are often discovered at an advanced stage and existing definitions of COPD and IPF can be misleading. To halt or reverse disease progression and achieve lung regeneration, there is a need for earlier identification and treatment of these diseases. A precision medicine approach to treatment is also important, involving the recognition of disease subtypes, or endotypes, according to underlying disease mechanisms, rather than the current "one-size-fits-all" approach. This review is based on discussions at a meeting involving 38 leading global experts in chronic lung disease mechanisms, and describes advances in the understanding of the pathology and molecular mechanisms of COPD and IPF to identify potential targets for reversing disease degeneration and promoting tissue repair and lung regeneration. We also discuss limitations of existing disease measures, technical advances in understanding disease pathology, and novel methods for targeted drug delivery.COPD and idiopathic pulmonary fibrosis (IPF) together represent a considerable unmet medical need, and advances in their treatment lag well behind those of other chronic conditions. Both diseases involve maladaptive repair mechanisms leading to progressive and irreversible damage. However, our understanding of the complex underlying disease mechanisms is incomplete; with current diagnostic approaches, COPD and IPF are often discovered at an advanced stage and existing definitions of COPD and IPF can be misleading. To halt or reverse disease progression and achieve lung regeneration, there is a need for earlier identification and treatment of these diseases. A precision medicine approach to treatment is also important, involving the recognition of disease subtypes, or endotypes, according to underlying disease mechanisms, rather than the current "one-size-fits-all" approach. This review is based on discussions at a meeting involving 38 leading global experts in chronic lung disease mechanisms, and describes advances in the understanding of the pathology and molecular mechanisms of COPD and IPF to identify potential targets for reversing disease degeneration and promoting tissue repair and lung regeneration. We also discuss limitations of existing disease measures, technical advances in understanding disease pathology, and novel methods for targeted drug delivery.
COPD and idiopathic pulmonary fibrosis (IPF) together represent a considerable unmet medical need, and advances in their treatment lag well behind those of other chronic conditions. Both diseases involve maladaptive repair mechanisms leading to progressive and irreversible damage. However, our understanding of the complex underlying disease mechanisms is incomplete; with current diagnostic approaches, COPD and IPF are often discovered at an advanced stage and existing definitions of COPD and IPF can be misleading. To halt or reverse disease progression and achieve lung regeneration, there is a need for earlier identification and treatment of these diseases. A precision medicine approach to treatment is also important, involving the recognition of disease subtypes, or endotypes, according to underlying disease mechanisms, rather than the current “one-size-fits-all” approach. This review is based on discussions at a meeting involving 38 leading global experts in chronic lung disease mechanisms, and describes advances in the understanding of the pathology and molecular mechanisms of COPD and IPF to identify potential targets for reversing disease degeneration and promoting tissue repair and lung regeneration. We also discuss limitations of existing disease measures, technical advances in understanding disease pathology, and novel methods for targeted drug delivery. Treatment outcomes with COPD and IPF are suboptimal. Better understanding of the diseases, such as targetable repair mechanisms, may generate novel therapies, and earlier diagnosis and treatment is needed to stop or even reverse disease progression. https://bit.ly/2Ga8J1g
Author Anderson, Gary P.
Fagerås, Malin
Belvisi, Maria G.
Barnes, Peter J.
AuthorAffiliation 3 AstraZeneca, Gothenburg, Sweden
4 Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
2 Lung Health Research Centre, University of Melbourne, Melbourne, Australia
1 National Heart & Lung Institute, Imperial College London, London, UK
AuthorAffiliation_xml – name: 2 Lung Health Research Centre, University of Melbourne, Melbourne, Australia
– name: 4 Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
– name: 1 National Heart & Lung Institute, Imperial College London, London, UK
– name: 3 AstraZeneca, Gothenburg, Sweden
Author_xml – sequence: 1
  givenname: Peter J.
  surname: Barnes
  fullname: Barnes, Peter J.
– sequence: 2
  givenname: Gary P.
  surname: Anderson
  fullname: Anderson, Gary P.
– sequence: 3
  givenname: Malin
  surname: Fagerås
  fullname: Fagerås, Malin
– sequence: 4
  givenname: Maria G.
  surname: Belvisi
  fullname: Belvisi, Maria G.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33408088$$D View this record in MEDLINE/PubMed
BookMark eNp9kc1v1DAQxS1URLeFf4ADypFLyvgrsRFCQis-KlXiAmdrYk-2rrJxsLOV-O9Jum1FOXCy9Pzeb0bzztjJmEZi7DWHC86NfMcbAGh4ewGCy1qAgGdss4r1qp6wDVjQteUGTtlZKTcAChpoX7BTKRUYMGbDPmyvcxqjr4bDuKtCLISFyvtqyqlM5OdS9SlXmXY0UsY5prHCMSzChDG_ZM97HAq9un_P2c8vn39sv9VX379ebj9d1V41Zq47G1AFRFQieEFa6b7rEXujKRgCoY23QkofyAauTNsFj1py1UrlqbMkz9nlkRsS3rgpxz3m3y5hdHdCyjuHeY5-INej6YzXbau9UeQNWi81F6j6HqyS3cL6eGRNh25PwdM4ZxyeQJ_-jPHa7dKts8oYq_QCeHsPyOnXgcrs9rF4GgYcKR2KE6ptuGi1gsX65u9Zj0Mezr8YxNHgl3OXTP2jhYNbO3YPHbu1Y7d2vITMPyEf57tqln3j8L_oH6yLq44
CitedBy_id crossref_primary_10_1007_s10753_024_02077_4
crossref_primary_10_1016_j_biopha_2021_112216
crossref_primary_10_1038_s41467_023_44184_0
crossref_primary_10_1126_sciadv_abp8322
crossref_primary_10_3390_cancers14153819
crossref_primary_10_3390_antiox11101885
crossref_primary_10_1007_s40264_024_01400_0
crossref_primary_10_3390_microorganisms12102030
crossref_primary_10_1186_s12931_022_02146_y
crossref_primary_10_23736_S0026_4806_22_08024_7
crossref_primary_10_1186_s12950_022_00308_9
crossref_primary_10_1017_erm_2022_27
crossref_primary_10_1016_j_arr_2024_102294
crossref_primary_10_1016_j_jconrel_2024_05_043
Cites_doi 10.1016/j.rmed.2017.07.062
10.1164/rccm.201605-0904OC
10.1378/chest.14-0373
10.1136/thoraxjnl-2013-204778
10.1371/journal.pone.0002142
10.1038/srep35871
10.1016/S0140-6736(11)60052-4
10.1183/09031936.00069712
10.1183/09031936.03.00119103
10.5966/sctm.2015-0337
10.1016/S0140-6736(06)68516-4
10.1007/s41030-015-0009-4
10.1165/rcmb.2016-0284OC
10.1164/rccm.201707-1519oc
10.1016/j.jaci.2016.08.004
10.1093/aje/152.4.307
10.1016/j.matbio.2018.01.023
10.1164/ajrccm.155.1.9001319
10.1016/S0140-6736(04)16900-6
10.1084/jem.20162152
10.1002/dvdy.10222
10.1136/bmjresp-2018-000397
10.1016/j.ajpath.2014.01.012
10.1371/journal.pgen.1003228
10.1242/dev.125.7.1315
10.1016/j.ijrobp.2017.02.216
10.1183/09031936.03.00089403
10.1056/NEJMra1705751
10.1183/16000617.0010-2019
10.1016/S0140-6736(08)61452-X
10.1378/chest.11-2348
10.1183/16000617.0122-2018
10.1016/j.rmed.2016.05.005
10.1021/acschembio.5b00216
10.1016/j.biopha.2019.108756
10.1016/j.mric.2015.01.003
10.2147/COPD.S131847
10.1038/s41467-018-07768-9
10.1164/rccm.201704-0667OC
10.1039/c2ib00149g
10.1165/rcmb.2006-0029OC
10.1016/j.rmed.2018.05.004
10.1172/jci.insight.93203
10.1146/annurev.physiol.65.092101.142446
10.3389/fmed.2018.00087
10.1136/thoraxjnl-2018-212630
10.1002/jmri.20876
10.1183/09031936.00007915
10.1152/japplphysiol.00732.2006
10.1002/mrm.26279
10.1371/journal.pone.0037483
10.1371/journal.pbio.2000731
10.1183/13993003.00026-2015
10.1164/rccm.201811-2083OC
10.1152/ajplung.00423.2015
10.1016/j.reprotox.2017.05.014
10.1001/jama.2018.13103
10.1126/scitranslmed.aal3765
10.1242/dmm.006031
10.1378/chest.130.5.1334
10.1016/S2213-2600(18)30196-6
10.1186/s12890-017-0468-5
10.1093/eurheartj/ehw272
10.1016/S2213-2600(17)30430-7
10.1016/S2213-2600(15)00283-0
10.1056/NEJMoa1106955
10.1111/crj.12147
10.1172/jci33950
10.1186/s12931-018-0717-z
10.1186/s12931-017-0699-2
10.1183/09031936.04.00014304
10.1016/j.pharmthera.2018.11.008
10.1164/rccm.201506-1063ST
10.1038/ncomms14532
10.1164/rccm.200712-1776OC
10.1183/09031936.00077309
10.1016/S2213-2600(13)70045-6
10.1164/rccm.201208-1361OC
10.1038/nrdp.2015.76
10.1172/jci.insight.123614
10.1016/S2213-2600(18)30135-8
10.12688/f1000research.7018.1
10.1164/rccm.201806-1166PP
10.1007/s12149-014-0913-y
10.1164/rccm.200910-1560OC
10.1016/S0002-9440(10)63147-1
10.1016/S2213-2600(15)00048-X
10.1016/j.rmed.2004.12.010
10.1164/rccm.201104-0597OC
10.1136/thoraxjnl-2014-206084
10.1164/rccm.201810-1975TR
10.2147/IJN.S182384
10.1172/JCI98224
10.1096/fj.201800965R
10.1164/rccm.201808-1557ED
10.1038/s41598-018-21727-w
10.1007/s40291-019-00413-1
10.1016/j.mam.2017.11.005
10.1186/1465-9921-9-52
10.1183/09059180.00000813
10.1111/all.13760
10.1016/j.chest.2018.08.1021
10.1016/j.rmed.2015.09.006
10.1016/j.ebiom.2018.12.052
10.1152/ajplung.00037.2018
10.1152/ajplung.00097.2010
10.1016/j.ejim.2019.07.005
10.1038/nm.2971
10.1038/s41598-017-02871-1
10.1038/nrd.2017.244
10.1096/fj.08-125468
10.1164/rccm.201712-2551OC
10.1056/NEJMoa1013660
10.1111/jcmm.12672
10.1634/theoncologist.2009-0042
10.1007/978-1-4939-3753-0_19
10.1513/AnnalsATS.201808-533MG
10.1136/thoraxjnl-2018-211851
10.2147/COPD.S164285
10.1136/thoraxjnl-2016-209753
10.1517/13543784.2013.778972
10.1016/j.chest.2018.07.030
10.1155/2017/3520581
10.1084/jem.20160675
10.3390/molecules22010139
10.1136/thoraxjnl-2016-208846
10.1097/MCP.0000000000000553
10.2967/jnumed.116.184796
10.1164/ajrccm.165.5.2106123
10.1159/000475780
10.1111/resp.13527
10.1183/09031936.00161911
10.1186/s12931-017-0642-6
10.18632/aging.100807
10.1016/S0140-6736(12)61144-1
10.1016/J.PHARMTHERA.2017.10.005
10.1007/s12325-018-0693-1
ContentType Journal Article
Copyright Copyright ©ERS 2021.
Copyright ©ERS 2021. 2021
Copyright_xml – notice: Copyright ©ERS 2021.
– notice: Copyright ©ERS 2021. 2021
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.1183/16000617.0213-2020
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList CrossRef

PubMed
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Chronic lung diseases: regeneration and repair
EISSN 1600-0617
ExternalDocumentID oai_doaj_org_article_fa8b8c5775c84ec8a9c3512a4ff0943b
PMC9488945
33408088
10_1183_16000617_0213_2020
Genre Journal Article
Review
GroupedDBID ---
29G
2WC
5GY
5VS
6~0
6~1
AAYXX
ABOCM
ABSQV
ACEMG
ADBBV
ADMOG
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BCNDV
BTFSW
CITATION
DIK
DU5
E3Z
EBS
EE-
EJD
F5P
F9R
GROUPED_DOAJ
GX1
H13
INIJC
KQ8
OK1
R0Z
RHI
RNS
RPM
TER
TR2
W8F
WOQ
AIPOO
M~E
NPM
RHF
7X8
5PM
ID FETCH-LOGICAL-c468t-b9da4daaa42dc2e545fbfaaf85ed8e0258c9233cde9d1487bdca5314734ceb9e3
IEDL.DBID DOA
ISSN 0905-9180
1600-0617
IngestDate Wed Aug 27 01:29:09 EDT 2025
Thu Aug 21 18:39:39 EDT 2025
Thu Sep 04 16:36:33 EDT 2025
Wed Feb 19 02:29:59 EST 2025
Thu Apr 24 22:57:55 EDT 2025
Wed Aug 20 07:40:31 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 159
Language English
License Copyright ©ERS 2021.
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c468t-b9da4daaa42dc2e545fbfaaf85ed8e0258c9233cde9d1487bdca5314734ceb9e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
OpenAccessLink https://doaj.org/article/fa8b8c5775c84ec8a9c3512a4ff0943b
PMID 33408088
PQID 2476127540
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_fa8b8c5775c84ec8a9c3512a4ff0943b
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9488945
proquest_miscellaneous_2476127540
pubmed_primary_33408088
crossref_primary_10_1183_16000617_0213_2020
crossref_citationtrail_10_1183_16000617_0213_2020
PublicationCentury 2000
PublicationDate 2021-03-31
PublicationDateYYYYMMDD 2021-03-31
PublicationDate_xml – month: 03
  year: 2021
  text: 2021-03-31
  day: 31
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle European respiratory review
PublicationTitleAlternate Eur Respir Rev
PublicationYear 2021
Publisher European Respiratory Society
Publisher_xml – name: European Respiratory Society
References Liao (2024102403514714000_30.159.200213.54) 2017; 22
Moon (2024102403514714000_30.159.200213.50) 2018; 41
Lee (2024102403514714000_30.159.200213.53) 2018; 41
Huang (2024102403514714000_30.159.200213.97) 2019; 196
Skronska-Wasek (2024102403514714000_30.159.200213.119) 2017; 196
Ohno (2024102403514714000_30.159.200213.55) 2016; 1448
Weatherley (2024102403514714000_30.159.200213.65) 2018; 74
2024102403514714000_30.159.200213.85
Houssaini (2024102403514714000_30.159.200213.109) 2018; 3
2024102403514714000_30.159.200213.88
Bell (2024102403514714000_30.159.200213.76) 2018; 13
2024102403514714000_30.159.200213.84
Martinez (2024102403514714000_30.159.200213.43) 2018; 154
Spagnolo (2024102403514714000_30.159.200213.45) 2015; 1
Chan (2024102403514714000_30.159.200213.64) 2017; 77
2024102403514714000_30.159.200213.74
Roos (2024102403514714000_30.159.200213.66) 2015; 23
2024102403514714000_30.159.200213.75
2024102403514714000_30.159.200213.77
2024102403514714000_30.159.200213.71
Wells (2024102403514714000_30.159.200213.87) 2018; 3
Dressen (2024102403514714000_30.159.200213.26) 2018; 6
2024102403514714000_30.159.200213.72
Kärkkäinen (2024102403514714000_30.159.200213.24) 2017; 18
2024102403514714000_30.159.200213.78
Garudadri (2024102403514714000_30.159.200213.79) 2018; 15
Kato (2024102403514714000_30.159.200213.137) 2015; 19
Vukmirovic (2024102403514714000_30.159.200213.41) 2018; 5
Vasilescu (2024102403514714000_30.159.200213.62) 2019; 200
Drakopanagiotakis (2024102403514714000_30.159.200213.81) 2018; 68–69
Shaykhiev (2024102403514714000_30.159.200213.128) 2019; 199
2024102403514714000_30.159.200213.20
2024102403514714000_30.159.200213.21
Piersma (2024102403514714000_30.159.200213.131) 2017; 72
2024102403514714000_30.159.200213.22
Selman (2024102403514714000_30.159.200213.38) 2018; 199
2024102403514714000_30.159.200213.28
Barnes (2024102403514714000_30.159.200213.4) 2015; 1
2024102403514714000_30.159.200213.29
Chen (2024102403514714000_30.159.200213.73) 2015; 109
2024102403514714000_30.159.200213.8
2024102403514714000_30.159.200213.23
Yanai (2024102403514714000_30.159.200213.112) 2015; 7
2024102403514714000_30.159.200213.25
2024102403514714000_30.159.200213.9
Obeidat (2024102403514714000_30.159.200213.93) 2017; 57
Cantor (2024102403514714000_30.159.200213.96) 2019; 155
2024102403514714000_30.159.200213.6
Johns (2024102403514714000_30.159.200213.10) 2014; 6
2024102403514714000_30.159.200213.5
2024102403514714000_30.159.200213.2
2024102403514714000_30.159.200213.1
Strongman (2024102403514714000_30.159.200213.3) 2018; 35
Burkes (2024102403514714000_30.159.200213.57) 2019; 25
Sauleda (2024102403514714000_30.159.200213.89) 2018; 6
Jenkins (2024102403514714000_30.159.200213.90) 2015; 3
2024102403514714000_30.159.200213.146
2024102403514714000_30.159.200213.147
Hess (2024102403514714000_30.159.200213.44) 2016; 3
2024102403514714000_30.159.200213.98
Tsantikos (2024102403514714000_30.159.200213.101) 2018; 128
2024102403514714000_30.159.200213.148
2024102403514714000_30.159.200213.11
2024102403514714000_30.159.200213.149
2024102403514714000_30.159.200213.92
Barnes (2024102403514714000_30.159.200213.105) 2019; 200
2024102403514714000_30.159.200213.143
Zhang (2024102403514714000_30.159.200213.49) 2019; 113
2024102403514714000_30.159.200213.94
2024102403514714000_30.159.200213.144
2024102403514714000_30.159.200213.95
2024102403514714000_30.159.200213.16
2024102403514714000_30.159.200213.17
2024102403514714000_30.159.200213.18
2024102403514714000_30.159.200213.140
Calvi (2024102403514714000_30.159.200213.139) 2013; 9
2024102403514714000_30.159.200213.141
2024102403514714000_30.159.200213.13
Moses (2024102403514714000_30.159.200213.52) 2019; 24
Fuschillo (2024102403514714000_30.159.200213.80) 2019; 68
2024102403514714000_30.159.200213.129
2024102403514714000_30.159.200213.135
2024102403514714000_30.159.200213.42
Pisi (2024102403514714000_30.159.200213.70) 2015; 10
2024102403514714000_30.159.200213.138
Fawzy (2024102403514714000_30.159.200213.86) 2018; 19
2024102403514714000_30.159.200213.132
2024102403514714000_30.159.200213.133
2024102403514714000_30.159.200213.134
Cazzola (2024102403514714000_30.159.200213.82) 2019; 23
Noth (2024102403514714000_30.159.200213.19) 2013; 1
2024102403514714000_30.159.200213.130
2024102403514714000_30.159.200213.46
2024102403514714000_30.159.200213.47
2024102403514714000_30.159.200213.48
Barnes (2024102403514714000_30.159.200213.40) 2019; 74
Naseri (2024102403514714000_30.159.200213.56) 2018; 13
Wang (2024102403514714000_30.159.200213.15) 2015; 9
Lowe (2024102403514714000_30.159.200213.60) 2019; 6
2024102403514714000_30.159.200213.117
2024102403514714000_30.159.200213.118
Ohmichi (2024102403514714000_30.159.200213.136) 1998; 125
2024102403514714000_30.159.200213.30
2024102403514714000_30.159.200213.124
2024102403514714000_30.159.200213.31
2024102403514714000_30.159.200213.32
2024102403514714000_30.159.200213.127
2024102403514714000_30.159.200213.120
2024102403514714000_30.159.200213.121
2024102403514714000_30.159.200213.123
2024102403514714000_30.159.200213.39
2024102403514714000_30.159.200213.34
2024102403514714000_30.159.200213.35
2024102403514714000_30.159.200213.36
2024102403514714000_30.159.200213.37
Pan (2024102403514714000_30.159.200213.99) 2017; 99
Lipworth (2024102403514714000_30.159.200213.58) 2018; 139
Bajc (2024102403514714000_30.159.200213.67) 2017; 12
Hoff (2024102403514714000_30.159.200213.61) 2017; 7
2024102403514714000_30.159.200213.107
Shi (2024102403514714000_30.159.200213.122) 2017; 2017
2024102403514714000_30.159.200213.63
2024102403514714000_30.159.200213.113
Anderson (2024102403514714000_30.159.200213.14) 2016; 5
2024102403514714000_30.159.200213.114
Maher (2024102403514714000_30.159.200213.91) 2017; 5
2024102403514714000_30.159.200213.116
Kadota (2024102403514714000_30.159.200213.110) 2018; 60
2024102403514714000_30.159.200213.111
Magnini (2024102403514714000_30.159.200213.83) 2017; 93
Balestrini (2024102403514714000_30.159.200213.145) 2012; 4
2024102403514714000_30.159.200213.68
2024102403514714000_30.159.200213.69
Ghosh (2024102403514714000_30.159.200213.125) 2018; 197
Maher (2024102403514714000_30.159.200213.33) 2017; 17
Weeden (2024102403514714000_30.159.200213.126) 2017; 15
Papaioannou (2024102403514714000_30.159.200213.27) 2016; 117
Baker (2024102403514714000_30.159.200213.108) 2019; 33
2024102403514714000_30.159.200213.102
2024102403514714000_30.159.200213.103
Wain (2024102403514714000_30.159.200213.12) 2015; 3
2024102403514714000_30.159.200213.104
Chakraborty (2024102403514714000_30.159.200213.142) 2013; 22
2024102403514714000_30.159.200213.100
2024102403514714000_30.159.200213.51
Baker (2024102403514714000_30.159.200213.106) 2016; 6
Koo (2024102403514714000_30.159.200213.7) 2018; 6
Justice (2024102403514714000_30.159.200213.115) 2019; 40
2024102403514714000_30.159.200213.59
References_xml – ident: 2024102403514714000_30.159.200213.32
  doi: 10.1016/j.rmed.2017.07.062
– volume: 196
  start-page: 172
  year: 2017
  ident: 2024102403514714000_30.159.200213.119
  article-title: Reduced frizzled receptor 4 expression prevents WNT/β-catenin-driven alveolar lung repair in chronic obstructive pulmonary disease
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.201605-0904OC
– ident: 2024102403514714000_30.159.200213.141
  doi: 10.1378/chest.14-0373
– ident: 2024102403514714000_30.159.200213.85
  doi: 10.1136/thoraxjnl-2013-204778
– ident: 2024102403514714000_30.159.200213.120
  doi: 10.1371/journal.pone.0002142
– volume: 6
  start-page: 35871
  year: 2016
  ident: 2024102403514714000_30.159.200213.106
  article-title: Oxidative stress dependent microRNA-34a activation via PI3Kalpha reduces the expression of sirtuin-1 and sirtuin-6 in epithelial cells
  publication-title: Sci Rep
  doi: 10.1038/srep35871
– volume: 41
  start-page: 933
  year: 2018
  ident: 2024102403514714000_30.159.200213.50
  article-title: Chemically induced cellular proteolysis: an emerging therapeutic strategy for undruggable targets
  publication-title: Mol Cells
– ident: 2024102403514714000_30.159.200213.21
  doi: 10.1016/S0140-6736(11)60052-4
– ident: 2024102403514714000_30.159.200213.74
  doi: 10.1183/09031936.00069712
– ident: 2024102403514714000_30.159.200213.47
  doi: 10.1183/09031936.03.00119103
– ident: 2024102403514714000_30.159.200213.140
  doi: 10.5966/sctm.2015-0337
– ident: 2024102403514714000_30.159.200213.11
  doi: 10.1016/S0140-6736(06)68516-4
– volume: 1
  start-page: 1
  year: 2015
  ident: 2024102403514714000_30.159.200213.45
  article-title: Current and future therapies for idiopathic pulmonary fibrosis
  publication-title: Pulm Ther
  doi: 10.1007/s41030-015-0009-4
– ident: 2024102403514714000_30.159.200213.1
– volume: 57
  start-page: 411
  year: 2017
  ident: 2024102403514714000_30.159.200213.93
  article-title: Integrative genomics of emphysema-associated genes reveals potential disease biomarkers
  publication-title: Am J Respir Cell Mol Biol
  doi: 10.1165/rcmb.2016-0284OC
– ident: 2024102403514714000_30.159.200213.143
  doi: 10.1164/rccm.201707-1519oc
– ident: 2024102403514714000_30.159.200213.77
  doi: 10.1016/j.jaci.2016.08.004
– ident: 2024102403514714000_30.159.200213.149
  doi: 10.1093/aje/152.4.307
– volume: 68–69
  start-page: 404
  year: 2018
  ident: 2024102403514714000_30.159.200213.81
  article-title: Biomarkers in idiopathic pulmonary fibrosis
  publication-title: Matrix Biol
  doi: 10.1016/j.matbio.2018.01.023
– ident: 2024102403514714000_30.159.200213.23
  doi: 10.1164/ajrccm.155.1.9001319
– ident: 2024102403514714000_30.159.200213.5
  doi: 10.1016/S0140-6736(04)16900-6
– ident: 2024102403514714000_30.159.200213.20
  doi: 10.1084/jem.20162152
– ident: 2024102403514714000_30.159.200213.130
  doi: 10.1002/dvdy.10222
– ident: 2024102403514714000_30.159.200213.35
  doi: 10.1136/bmjresp-2018-000397
– volume: 6
  start-page: 384
  year: 2019
  ident: 2024102403514714000_30.159.200213.60
  article-title: COPDGene® 2019: redefining the diagnosis of chronic obstructive pulmonary disease
  publication-title: Chronic Obstr Pulm Dis
– ident: 2024102403514714000_30.159.200213.129
  doi: 10.1016/j.ajpath.2014.01.012
– volume: 9
  start-page: e1003228
  year: 2013
  ident: 2024102403514714000_30.159.200213.139
  article-title: Hepatocyte growth factor, a determinant of airspace homeostasis in the murine lung
  publication-title: PLoS Genet
  doi: 10.1371/journal.pgen.1003228
– volume: 125
  start-page: 1315
  year: 1998
  ident: 2024102403514714000_30.159.200213.136
  article-title: Hepatocyte growth factor (HGF) acts as a mesenchyme-derived morphogenic factor during fetal lung development
  publication-title: Development
  doi: 10.1242/dev.125.7.1315
– volume: 99
  start-page: 353
  year: 2017
  ident: 2024102403514714000_30.159.200213.99
  article-title: Inhibition of Bcl-2/xl with ABT-263 selectively kills senescent type II pneumocytes and reverses persistent pulmonary fibrosis induced by ionizing radiation in mice
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2017.02.216
– ident: 2024102403514714000_30.159.200213.71
  doi: 10.1183/09031936.03.00089403
– ident: 2024102403514714000_30.159.200213.18
  doi: 10.1056/NEJMra1705751
– ident: 2024102403514714000_30.159.200213.9
  doi: 10.1183/16000617.0010-2019
– volume: 6
  start-page: 1557
  year: 2014
  ident: 2024102403514714000_30.159.200213.10
  article-title: Diagnosis and early detection of COPD using spirometry
  publication-title: J Thorac Dis
– ident: 2024102403514714000_30.159.200213.39
  doi: 10.1016/S0140-6736(08)61452-X
– ident: 2024102403514714000_30.159.200213.16
  doi: 10.1378/chest.11-2348
– ident: 2024102403514714000_30.159.200213.75
  doi: 10.1183/16000617.0122-2018
– volume: 117
  start-page: 14
  year: 2016
  ident: 2024102403514714000_30.159.200213.27
  article-title: Combined pulmonary fibrosis and emphysema: the many aspects of a cohabitation contract
  publication-title: Respir Med
  doi: 10.1016/j.rmed.2016.05.005
– ident: 2024102403514714000_30.159.200213.51
  doi: 10.1021/acschembio.5b00216
– volume: 113
  start-page: 108756
  year: 2019
  ident: 2024102403514714000_30.159.200213.49
  article-title: Interleukin-18 promotes fibroblast senescence in pulmonary fibrosis through down-regulating Klotho expression
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2019.108756
– volume: 23
  start-page: 217
  year: 2015
  ident: 2024102403514714000_30.159.200213.66
  article-title: Hyperpolarized gas MR imaging: technique and applications
  publication-title: Magn Reson Imaging Clin N Am
  doi: 10.1016/j.mric.2015.01.003
– volume: 12
  start-page: 1579
  year: 2017
  ident: 2024102403514714000_30.159.200213.67
  article-title: Identifying the heterogeneity of COPD by V/P SPECT: a new tool for improving the diagnosis of parenchymal defects and grading the severity of small airways disease
  publication-title: Int J Chron Obstruct Pulmon Dis
  doi: 10.2147/COPD.S131847
– ident: 2024102403514714000_30.159.200213.92
  doi: 10.1038/s41467-018-07768-9
– volume: 197
  start-page: 885
  year: 2018
  ident: 2024102403514714000_30.159.200213.125
  article-title: Exhaustion of airway basal progenitor cells in early and established chronic obstructive pulmonary disease
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.201704-0667OC
– volume: 4
  start-page: 410
  year: 2012
  ident: 2024102403514714000_30.159.200213.145
  article-title: The mechanical memory of lung myofibroblasts
  publication-title: Integr Biol (Camb)
  doi: 10.1039/c2ib00149g
– ident: 2024102403514714000_30.159.200213.48
  doi: 10.1165/rcmb.2006-0029OC
– volume: 139
  start-page: 106
  year: 2018
  ident: 2024102403514714000_30.159.200213.58
  article-title: What can we learn about COPD from impulse oscillometry?
  publication-title: Respir Med
  doi: 10.1016/j.rmed.2018.05.004
– volume: 3
  start-page: e93203
  year: 2018
  ident: 2024102403514714000_30.159.200213.109
  article-title: mTOR pathway activation drives lung cell senescence and emphysema
  publication-title: JCI Insight
  doi: 10.1172/jci.insight.93203
– ident: 2024102403514714000_30.159.200213.117
  doi: 10.1146/annurev.physiol.65.092101.142446
– volume: 5
  start-page: 87
  year: 2018
  ident: 2024102403514714000_30.159.200213.41
  article-title: Impact of transcriptomics on our understanding of pulmonary fibrosis
  publication-title: Front Med (Lausanne)
  doi: 10.3389/fmed.2018.00087
– ident: 2024102403514714000_30.159.200213.46
  doi: 10.1136/thoraxjnl-2018-212630
– ident: 2024102403514714000_30.159.200213.59
  doi: 10.1002/jmri.20876
– ident: 2024102403514714000_30.159.200213.146
  doi: 10.1183/09031936.00007915
– ident: 2024102403514714000_30.159.200213.68
  doi: 10.1152/japplphysiol.00732.2006
– ident: 2024102403514714000_30.159.200213.37
– volume: 77
  start-page: 1916
  year: 2017
  ident: 2024102403514714000_30.159.200213.64
  article-title: Whole lung morphometry with 3D multiple b-value hyperpolarized gas MRI and compressed sensing
  publication-title: Magn Reson Med
  doi: 10.1002/mrm.26279
– ident: 2024102403514714000_30.159.200213.88
  doi: 10.1371/journal.pone.0037483
– volume: 15
  start-page: e2000731
  year: 2017
  ident: 2024102403514714000_30.159.200213.126
  article-title: Lung basal stem cells rapidly repair DNA damage using the error-prone nonhomologous end-joining pathway
  publication-title: PLoS Biol
  doi: 10.1371/journal.pbio.2000731
– ident: 2024102403514714000_30.159.200213.34
  doi: 10.1183/13993003.00026-2015
– volume: 200
  start-page: 575
  year: 2019
  ident: 2024102403514714000_30.159.200213.62
  article-title: Non-invasive imaging biomarker identifies small airway damage in severe COPD
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.201811-2083OC
– ident: 2024102403514714000_30.159.200213.138
  doi: 10.1152/ajplung.00423.2015
– volume: 72
  start-page: 53
  year: 2017
  ident: 2024102403514714000_30.159.200213.131
  article-title: Retinoic acid in developmental toxicology: teratogen, morphogen and biomarker
  publication-title: Reprod Toxicol
  doi: 10.1016/j.reprotox.2017.05.014
– ident: 2024102403514714000_30.159.200213.31
  doi: 10.1001/jama.2018.13103
– ident: 2024102403514714000_30.159.200213.100
  doi: 10.1126/scitranslmed.aal3765
– ident: 2024102403514714000_30.159.200213.123
  doi: 10.1242/dmm.006031
– ident: 2024102403514714000_30.159.200213.135
  doi: 10.1378/chest.130.5.1334
– volume: 6
  start-page: 591
  year: 2018
  ident: 2024102403514714000_30.159.200213.7
  article-title: Small airways disease in mild and moderate chronic obstructive pulmonary disease: a cross-sectional study
  publication-title: Lancet Respir Med
  doi: 10.1016/S2213-2600(18)30196-6
– volume: 17
  start-page: 124
  year: 2017
  ident: 2024102403514714000_30.159.200213.33
  article-title: Unmet needs in the treatment of idiopathic pulmonary fibrosis – insights from patient chart review in five European countries
  publication-title: BMC Pulm Med
  doi: 10.1186/s12890-017-0468-5
– ident: 2024102403514714000_30.159.200213.95
  doi: 10.1093/eurheartj/ehw272
– volume: 5
  start-page: 946
  year: 2017
  ident: 2024102403514714000_30.159.200213.91
  article-title: An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study
  publication-title: Lancet Respir Med
  doi: 10.1016/S2213-2600(17)30430-7
– volume: 3
  start-page: 473
  year: 2016
  ident: 2024102403514714000_30.159.200213.44
  article-title: Back to the future: past, present, and future is COPD360
  publication-title: Chronic Obstr Pulm Dis
– volume: 3
  start-page: 769
  year: 2015
  ident: 2024102403514714000_30.159.200213.12
  article-title: Novel insights into the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary disease (UK BiLEVE): a genetic association study in UK Biobank
  publication-title: Lancet Respir Med
  doi: 10.1016/S2213-2600(15)00283-0
– ident: 2024102403514714000_30.159.200213.6
  doi: 10.1056/NEJMoa1106955
– volume: 9
  start-page: 330
  year: 2015
  ident: 2024102403514714000_30.159.200213.15
  article-title: Imbalance of peripheral blood Th17 and Treg responses in patients with chronic obstructive pulmonary disease
  publication-title: Clin Respir J
  doi: 10.1111/crj.12147
– ident: 2024102403514714000_30.159.200213.121
  doi: 10.1172/jci33950
– volume: 19
  start-page: 20
  year: 2018
  ident: 2024102403514714000_30.159.200213.86
  article-title: Association of thrombocytosis with COPD morbidity: the SPIROMICS and COPDGene cohorts
  publication-title: Respir Res
  doi: 10.1186/s12931-018-0717-z
– ident: 2024102403514714000_30.159.200213.94
  doi: 10.1186/s12931-017-0699-2
– ident: 2024102403514714000_30.159.200213.42
  doi: 10.1183/09031936.04.00014304
– volume: 196
  start-page: 79
  year: 2019
  ident: 2024102403514714000_30.159.200213.97
  article-title: Activating Wnt/β-catenin signaling pathway for disease therapy: challenges and opportunities
  publication-title: Pharmacol Ther
  doi: 10.1016/j.pharmthera.2018.11.008
– ident: 2024102403514714000_30.159.200213.17
  doi: 10.1164/rccm.201506-1063ST
– ident: 2024102403514714000_30.159.200213.114
  doi: 10.1038/ncomms14532
– ident: 2024102403514714000_30.159.200213.72
  doi: 10.1164/rccm.200712-1776OC
– ident: 2024102403514714000_30.159.200213.2
  doi: 10.1183/09031936.00077309
– volume: 1
  start-page: 309
  year: 2013
  ident: 2024102403514714000_30.159.200213.19
  article-title: Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study
  publication-title: Lancet Respir Med
  doi: 10.1016/S2213-2600(13)70045-6
– ident: 2024102403514714000_30.159.200213.111
  doi: 10.1164/rccm.201208-1361OC
– volume: 1
  start-page: 15076
  year: 2015
  ident: 2024102403514714000_30.159.200213.4
  article-title: Chronic obstructive pulmonary disease
  publication-title: Nat Rev Dis Primers
  doi: 10.1038/nrdp.2015.76
– volume: 3
  start-page: e123614
  year: 2018
  ident: 2024102403514714000_30.159.200213.87
  article-title: Elevated circulating MMP-9 is linked to increased COPD exacerbation risk in SPIROMICS and COPDGene
  publication-title: JCI Insight
  doi: 10.1172/jci.insight.123614
– volume: 6
  start-page: 603
  year: 2018
  ident: 2024102403514714000_30.159.200213.26
  article-title: Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study
  publication-title: Lancet Respir Med
  doi: 10.1016/S2213-2600(18)30135-8
– volume: 5
  start-page: 2392
  year: 2016
  ident: 2024102403514714000_30.159.200213.14
  article-title: Advances in understanding COPD
  publication-title: F1000Res
  doi: 10.12688/f1000research.7018.1
– volume: 41
  start-page: 943
  year: 2018
  ident: 2024102403514714000_30.159.200213.53
  article-title: CRISPR and target-specific DNA endonucleases for efficient DNA knock-in in eukaryotic genomes
  publication-title: Mol Cells
– volume: 199
  start-page: 279
  year: 2018
  ident: 2024102403514714000_30.159.200213.38
  article-title: Why does an aging smoker's lung develop idiopathic pulmonary fibrosis and not chronic obstructive pulmonary disease?
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.201806-1166PP
– ident: 2024102403514714000_30.159.200213.69
  doi: 10.1007/s12149-014-0913-y
– ident: 2024102403514714000_30.159.200213.98
  doi: 10.1164/rccm.200910-1560OC
– ident: 2024102403514714000_30.159.200213.124
  doi: 10.1016/S0002-9440(10)63147-1
– volume: 3
  start-page: 462
  year: 2015
  ident: 2024102403514714000_30.159.200213.90
  article-title: Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study
  publication-title: Lancet Respir Med
  doi: 10.1016/S2213-2600(15)00048-X
– ident: 2024102403514714000_30.159.200213.28
  doi: 10.1016/j.rmed.2004.12.010
– ident: 2024102403514714000_30.159.200213.78
  doi: 10.1164/rccm.201104-0597OC
– ident: 2024102403514714000_30.159.200213.102
  doi: 10.1136/thoraxjnl-2014-206084
– volume: 200
  start-page: 556
  year: 2019
  ident: 2024102403514714000_30.159.200213.105
  article-title: Cellular senescence as a mechanism and target in chronic lung diseases
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.201810-1975TR
– volume: 13
  start-page: 7727
  year: 2018
  ident: 2024102403514714000_30.159.200213.56
  article-title: Exosome-mediated delivery of functionally active miRNA-142-3p inhibitor reduces tumorigenicity of breast cancer in vitro and in vivo
  publication-title: Int J Nanomedicine
  doi: 10.2147/IJN.S182384
– volume: 128
  start-page: 2406
  year: 2018
  ident: 2024102403514714000_30.159.200213.101
  article-title: Granulocyte-CSF links destructive inflammation and comorbidities in obstructive lung disease
  publication-title: J Clin Invest
  doi: 10.1172/JCI98224
– volume: 33
  start-page: 1605
  year: 2019
  ident: 2024102403514714000_30.159.200213.108
  article-title: MicroRNA-570 is a novel regulator of cellular senescence and inflammaging
  publication-title: FASEB J
  doi: 10.1096/fj.201800965R
– ident: 2024102403514714000_30.159.200213.36
– volume: 199
  start-page: 555
  year: 2019
  ident: 2024102403514714000_30.159.200213.128
  article-title: Basal-like cells in the BAL fluid: an Echo of regenerative crisis in idiopathic pulmonary fibrosis lungs
  publication-title: Am J Respir Crit Care Med
  doi: 10.1164/rccm.201808-1557ED
– ident: 2024102403514714000_30.159.200213.144
  doi: 10.1038/s41598-018-21727-w
– volume: 23
  start-page: 603
  year: 2019
  ident: 2024102403514714000_30.159.200213.82
  article-title: Evolving concepts in chronic obstructive pulmonary disease blood-based biomarkers
  publication-title: Mol Diagn Ther
  doi: 10.1007/s40291-019-00413-1
– volume: 60
  start-page: 92
  year: 2018
  ident: 2024102403514714000_30.159.200213.110
  article-title: Emerging role of extracellular vesicles as a senescence-associated secretory phenotype: insights into the pathophysiology of lung diseases
  publication-title: Mol Aspects Med
  doi: 10.1016/j.mam.2017.11.005
– ident: 2024102403514714000_30.159.200213.13
  doi: 10.1186/1465-9921-9-52
– ident: 2024102403514714000_30.159.200213.29
  doi: 10.1183/09059180.00000813
– volume: 74
  start-page: 1249
  year: 2019
  ident: 2024102403514714000_30.159.200213.40
  article-title: Inflammatory endotypes in COPD
  publication-title: Allergy
  doi: 10.1111/all.13760
– volume: 154
  start-page: 978
  year: 2018
  ident: 2024102403514714000_30.159.200213.43
  article-title: Focus on idiopathic pulmonary fibrosis: advancing approaches to diagnosis, prognosis, and treatment
  publication-title: Chest
  doi: 10.1016/j.chest.2018.08.1021
– volume: 109
  start-page: 1446
  year: 2015
  ident: 2024102403514714000_30.159.200213.73
  article-title: Validation of human small airway measurements using endobronchial optical coherence tomography
  publication-title: Respir Med
  doi: 10.1016/j.rmed.2015.09.006
– volume: 40
  start-page: 554
  year: 2019
  ident: 2024102403514714000_30.159.200213.115
  article-title: Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study
  publication-title: EBioMed
  doi: 10.1016/j.ebiom.2018.12.052
– volume: 10
  start-page: 1191
  year: 2015
  ident: 2024102403514714000_30.159.200213.70
  article-title: Small airway dysfunction and flow and volume bronchodilator responsiveness in patients with chronic obstructive pulmonary disease
  publication-title: Int J Chron Obstruct Pulmon Dis
– volume: 6
  start-page: 110
  year: 2018
  ident: 2024102403514714000_30.159.200213.89
  article-title: Idiopathic pulmonary fibrosis: epidemiology, natural history, phenotypes
  publication-title: Med Sci
– ident: 2024102403514714000_30.159.200213.104
  doi: 10.1152/ajplung.00037.2018
– ident: 2024102403514714000_30.159.200213.113
  doi: 10.1152/ajplung.00097.2010
– volume: 68
  start-page: 1
  year: 2019
  ident: 2024102403514714000_30.159.200213.80
  article-title: Blood eosinophils as biomarkers of therapeutic response to chronic obstructive pulmonary disease: still work in progress
  publication-title: Eur J Intern Med
  doi: 10.1016/j.ejim.2019.07.005
– ident: 2024102403514714000_30.159.200213.8
  doi: 10.1038/nm.2971
– ident: 2024102403514714000_30.159.200213.148
– volume: 7
  start-page: 2999
  year: 2017
  ident: 2024102403514714000_30.159.200213.61
  article-title: CT-based local distribution metric improves characterization of COPD
  publication-title: Sci Rep
  doi: 10.1038/s41598-017-02871-1
– ident: 2024102403514714000_30.159.200213.147
  doi: 10.1038/nrd.2017.244
– ident: 2024102403514714000_30.159.200213.107
  doi: 10.1096/fj.08-125468
– ident: 2024102403514714000_30.159.200213.127
  doi: 10.1164/rccm.201712-2551OC
– ident: 2024102403514714000_30.159.200213.25
  doi: 10.1056/NEJMoa1013660
– volume: 19
  start-page: 2818
  year: 2015
  ident: 2024102403514714000_30.159.200213.137
  article-title: Bronchioalveolar morphogenesis of human bronchial epithelial cells depending upon hepatocyte growth factor
  publication-title: J Cell Mol Med
  doi: 10.1111/jcmm.12672
– ident: 2024102403514714000_30.159.200213.84
  doi: 10.1634/theoncologist.2009-0042
– volume: 1448
  start-page: 261
  year: 2016
  ident: 2024102403514714000_30.159.200213.55
  article-title: Exosome-mediated targeted delivery of miRNAs
  publication-title: Methods Mol Biol
  doi: 10.1007/978-1-4939-3753-0_19
– volume: 15
  start-page: S234
  year: 2018
  ident: 2024102403514714000_30.159.200213.79
  article-title: Targeting chronic obstructive pulmonary disease phenotypes, endotypes, and biomarkers
  publication-title: Ann Am Thorac Soc
  doi: 10.1513/AnnalsATS.201808-533MG
– volume: 74
  start-page: 500
  year: 2018
  ident: 2024102403514714000_30.159.200213.65
  article-title: Hyperpolarised xenon magnetic resonance spectroscopy for the longitudinal assessment of changes in gas diffusion in IPF
  publication-title: Thorax
  doi: 10.1136/thoraxjnl-2018-211851
– volume: 13
  start-page: 2113
  year: 2018
  ident: 2024102403514714000_30.159.200213.76
  article-title: Feasibility and challenges of using multiple breath washout in COPD
  publication-title: Int J Chron Obstruct Pulmon Dis
  doi: 10.2147/COPD.S164285
– ident: 2024102403514714000_30.159.200213.116
  doi: 10.1136/thoraxjnl-2016-209753
– volume: 22
  start-page: 499
  year: 2013
  ident: 2024102403514714000_30.159.200213.142
  article-title: Hepatocyte growth factor is an attractive target for the treatment of pulmonary fibrosis
  publication-title: Expert Opin Investig Drugs
  doi: 10.1517/13543784.2013.778972
– volume: 155
  start-page: 266
  year: 2019
  ident: 2024102403514714000_30.159.200213.96
  article-title: COPD pathogenesis: finding the common in the complex
  publication-title: Chest
  doi: 10.1016/j.chest.2018.07.030
– volume: 2017
  start-page: 3520581
  year: 2017
  ident: 2024102403514714000_30.159.200213.122
  article-title: Distinct roles of WNT/beta-catenin signaling in the pathogenesis of chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis
  publication-title: Mediators Inflamm
  doi: 10.1155/2017/3520581
– ident: 2024102403514714000_30.159.200213.118
  doi: 10.1084/jem.20160675
– volume: 22
  start-page: E139
  year: 2017
  ident: 2024102403514714000_30.159.200213.54
  article-title: Oligonucleotide therapy for obstructive and restrictive respiratory diseases
  publication-title: Molecules
  doi: 10.3390/molecules22010139
– ident: 2024102403514714000_30.159.200213.132
  doi: 10.1136/thoraxjnl-2016-208846
– volume: 25
  start-page: 132
  year: 2019
  ident: 2024102403514714000_30.159.200213.57
  article-title: Initiating drug therapy in early stage chronic obstructive pulmonary disease: does it impact the course and outcome?
  publication-title: Curr Opin Pulm Med
  doi: 10.1097/MCP.0000000000000553
– ident: 2024102403514714000_30.159.200213.63
  doi: 10.2967/jnumed.116.184796
– ident: 2024102403514714000_30.159.200213.134
  doi: 10.1164/ajrccm.165.5.2106123
– volume: 93
  start-page: 379
  year: 2017
  ident: 2024102403514714000_30.159.200213.83
  article-title: Idiopathic pulmonary fibrosis: molecular endotypes of fibrosis stratifying existing and emerging therapies
  publication-title: Respiration
  doi: 10.1159/000475780
– volume: 24
  start-page: 628
  year: 2019
  ident: 2024102403514714000_30.159.200213.52
  article-title: Applications of CRISPR systems in respiratory health: entering a new “red pen” era in genome editing
  publication-title: Respirology
  doi: 10.1111/resp.13527
– ident: 2024102403514714000_30.159.200213.30
– ident: 2024102403514714000_30.159.200213.133
  doi: 10.1183/09031936.00161911
– volume: 18
  start-page: 160
  year: 2017
  ident: 2024102403514714000_30.159.200213.24
  article-title: Effect of smoking and comorbidities on survival in idiopathic pulmonary fibrosis
  publication-title: Respir Res
  doi: 10.1186/s12931-017-0642-6
– volume: 7
  start-page: 664
  year: 2015
  ident: 2024102403514714000_30.159.200213.112
  article-title: Cellular senescence-like features of lung fibroblasts derived from idiopathic pulmonary fibrosis patients
  publication-title: Aging (Albany NY)
  doi: 10.18632/aging.100807
– ident: 2024102403514714000_30.159.200213.22
  doi: 10.1016/S0140-6736(12)61144-1
– ident: 2024102403514714000_30.159.200213.103
  doi: 10.1016/J.PHARMTHERA.2017.10.005
– volume: 35
  start-page: 724
  year: 2018
  ident: 2024102403514714000_30.159.200213.3
  article-title: Incidence, prevalence, and survival of patients with idiopathic pulmonary fibrosis in the UK
  publication-title: Adv Ther
  doi: 10.1007/s12325-018-0693-1
SSID ssj0040607
Score 2.3350227
SecondaryResourceType review_article
Snippet COPD and idiopathic pulmonary fibrosis (IPF) together represent a considerable unmet medical need, and advances in their treatment lag well behind those of...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 200213
SubjectTerms Reviews
Title Chronic lung diseases: prospects for regeneration and repair
URI https://www.ncbi.nlm.nih.gov/pubmed/33408088
https://www.proquest.com/docview/2476127540
https://pubmed.ncbi.nlm.nih.gov/PMC9488945
https://doaj.org/article/fa8b8c5775c84ec8a9c3512a4ff0943b
Volume 30
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1600-0617
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0040607
  issn: 0905-9180
  databaseCode: KQ8
  dateStart: 20050101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1600-0617
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0040607
  issn: 0905-9180
  databaseCode: DOA
  dateStart: 20130101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1600-0617
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0040607
  issn: 0905-9180
  databaseCode: DIK
  dateStart: 20050101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1600-0617
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0040607
  issn: 0905-9180
  databaseCode: GX1
  dateStart: 20050101
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 1600-0617
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0040607
  issn: 0905-9180
  databaseCode: RPM
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEA7iQbyIb9cXFbxJ3bZJmkS8qPhA0JMLewt5qiBVdtf_7yRpl10RvXjpoU1JmEe-CZn5BqHjmgMqwh6QW4J1Tqgrcq4YzrWhXrCSGh_ruB8e67sBuR_S4Uyrr5ATluiBk-D6XnHNDWWMGk6c4UoYDCCliPchKU6H3RdgrDtMpT0YUCoVSosidCLkRVcuw3G_rBNunwK6YTCS0Ol7BpIic_9P4eb3rMkZGLpZRStt_JhdpHWvoQXXrKOlh_aGfAOdt2y32Rt4cdZev4zPMpgoFlWOM4hSs5F7jnTTQSuZaiy8-FCvo000uLl-urrL2w4JuSE1n-RaWEWsUopU1lQOoiGvvVKeU2e5g3CGGwjgsLFOWDj3MG2NAqcjDBPjtHB4Cy02743bQVkVaHmEKXSlPAHQ1p7Vmuo6uGhBDOuhshOSNC19eOhi8SbjMYJj2QlWBsHKINgeOpn-85HIM34dfRlkPx0ZiK_jCzAH2ZqD_Msceuio05wERwm3H6px759jWRFWBzZ7AhNtJ01Op8KYQOTMeQ-xOR3PrWX-S_P6Esm4BeyAgtDd_1j8HlquQspMLHncR4uT0ac7gJhnog-jecPzdlh-Acqz_Dc
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Chronic+lung+diseases%3A+prospects+for+regeneration+and+repair&rft.jtitle=European+respiratory+review&rft.au=Barnes%2C+Peter+J.&rft.au=Anderson%2C+Gary+P.&rft.au=Fager%C3%A5s%2C+Malin&rft.au=Belvisi%2C+Maria+G.&rft.date=2021-03-31&rft.issn=0905-9180&rft.eissn=1600-0617&rft.volume=30&rft.issue=159&rft.spage=200213&rft_id=info:doi/10.1183%2F16000617.0213-2020&rft.externalDBID=n%2Fa&rft.externalDocID=10_1183_16000617_0213_2020
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0905-9180&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0905-9180&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0905-9180&client=summon